These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 17112875

  • 1. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
    Villamil F, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, Rossi M, Lake J, Munn S, Mühlbacher F, Leonardi L, Cillo U.
    Transplant Proc; 2006 Nov; 38(9):2964-7. PubMed ID: 17112875
    [Abstract] [Full Text] [Related]

  • 2. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 3. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C.
    Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310
    [Abstract] [Full Text] [Related]

  • 4. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK.
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [Abstract] [Full Text] [Related]

  • 5. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM, Lilly LB, Marotta PJ, Mason AL, Bilodeau M, Vaillancourt M.
    Ann Hepatol; 2013 Dec; 12(2):282-93. PubMed ID: 23396740
    [Abstract] [Full Text] [Related]

  • 6. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [Abstract] [Full Text] [Related]

  • 7. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [Abstract] [Full Text] [Related]

  • 8. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J, Fernández-Aguilar JL, Suárez Muñoz MA, González-Sánchez AJ, Pérez Daga JA, Ramírez Plaza CP, Carrasco Campos J, Jiménez Mazure C, Becerra Ortíz R.
    Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up in hepatitis C patients with respect to immunosuppression.
    Mueller AR, Platz KP, Berg T, Fukomoto T, Guckelberger O, Neuhaus R, Bechstein WO, Hopf U, Lobeck H, Neuhaus P.
    Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255
    [No Abstract] [Full Text] [Related]

  • 10. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P.
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [Abstract] [Full Text] [Related]

  • 11. HCV histological recurrence and survival following liver transplantation in patients with and without hepatocellular carcinoma.
    De Martin E, Senzolo M, Boninsegna S, Guido M, Masier A, Germani G, Tomat S, Brolese A, Neri D, Cillo U, Gambato M, Russo FP, Farinati F, Burra P.
    Transplant Proc; 2008 May; 40(6):1974-5. PubMed ID: 18675104
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up.
    Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P.
    Transplantation; 2004 Jan 27; 77(2):226-31. PubMed ID: 14742986
    [Abstract] [Full Text] [Related]

  • 13. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.
    Ann Surg; 2008 Nov 27; 248(5):857-62. PubMed ID: 18948815
    [Abstract] [Full Text] [Related]

  • 14. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.
    J Hepatol; 2006 Apr 27; 44(4):717-22. PubMed ID: 16487616
    [Abstract] [Full Text] [Related]

  • 15. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
    Burra P, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, Villamil F.
    Dig Liver Dis; 2009 May 27; 41(5):350-6. PubMed ID: 19046932
    [Abstract] [Full Text] [Related]

  • 16. Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis.
    Yosry A, Esmat G, El-Serafy M, Omar A, Doss W, Said M, Abdel-Bary A, Hosny A, Marawan I, El-Malt O, Kamel RR, Hatata Y, Ghali A, Sabri H, Kamel S, El-Gbaly H, Tanaka K.
    Transplant Proc; 2008 Jun 27; 40(5):1481-4. PubMed ID: 18589133
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study.
    Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C, Dumortier J, Salamé E, Calmus Y, Maugendre D, Diapason Study Group.
    Liver Transpl; 2007 Jan 27; 13(1):136-44. PubMed ID: 17192854
    [Abstract] [Full Text] [Related]

  • 18. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.
    Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A.
    Transpl Int; 2005 Dec 27; 18(12):1336-45. PubMed ID: 16297052
    [Abstract] [Full Text] [Related]

  • 19. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W, Albani J, Englert C, Spehr A, Grabhorn E, Kemper MJ, Burdelski M, Ganschow R.
    Pediatr Transplant; 2006 Dec 27; 10(8):938-42. PubMed ID: 17096762
    [Abstract] [Full Text] [Related]

  • 20. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient.
    Pollard S.
    Liver Int; 2004 Oct 27; 24(5):402-6. PubMed ID: 15482334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.